CSL shares down 5% after post-heart attack drug disappoints in late-stage test
12 Feb 2024
Phase 3AHAClinical Result
CSL’s cholesterol efflux enhancer failed to prevent repeat cardiac events in a Phase III study that recruited patients who had a recent myocardial infarction, prompting a drop in the company’s share price.
The Phase III AEGIS-II trial tested the drug, CSL112, against placebo in more than 18,200 patients in the 90-day high-risk period after a heart attack. The treatment missed the primary endpoint of reducing major adverse cardiovascular events (MACE) at 90 days. There were no major safety or tolerability concerns, CSL said in a company release.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.